Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs

By Harigai Masayoshi  

Modern Rheumatology, Vol. 23, Iss. 2, 2013-03 ,pp. : 284-296

Springer Publishing Company

Access to resources Recommend Favorite

Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

By Li Sophia   Kaur Primal   Chan Virginia   Berney Steven  

Clinical Rheumatology, Vol. 28, Iss. 7, 2009-07 ,pp. : 787-791

Springer Publishing Company

Access to resources Recommend Favorite

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

By Onishi Sachiko   Yoshio Taku   Nagashima Takao   Minota Seiji  

Modern Rheumatology, Vol. 20, Iss. 5, 2010-10 ,pp. : 528-530

Springer Publishing Company

Access to resources Recommend Favorite

Tumor necrosis factor-alpha and Interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients

By Ates Omer   Hatemi Gulen   Hamuryudan Vedat   Topal-Sarikaya Aysegul  

Clinical Rheumatology, Vol. 27, Iss. 10, 2008-10 ,pp. : 1243-1248

Springer Publishing Company

Access to resources Recommend Favorite

Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?

By Nagashima Takao   Minota Seiji  

Clinical Rheumatology, Vol. 29, Iss. 7, 2010-07 ,pp. : 819-820

Springer Publishing Company

Access to resources Recommend Favorite